Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes

International Journal of Obesity

Volumn 38, Issue 9, 2014, Pages 1221-1227

  Schlottmann, I ^a   Ehrhart Bornstein, M ^a   Wabitsch, M ^b   Bornstein, S R ^a   Lamounier Zepter, V ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

adipocyte fatty acid binding protein; adipocytes; adipokines; non classical secretion; secretory mechanism

Indexed keywords

CALCIUM; FATTY ACID BINDING PROTEIN 4; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

ADIPOCYTE; ARTICLE; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GOLGI COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SECRETORY PATHWAY; SIMPSON GOLABI BEHMEL SYNDROME; CALCIUM SIGNALING; CELL CULTURE; CONGENITAL HEART MALFORMATION; GIGANTISM; HEART ARRHYTHMIA; INTELLECTUAL IMPAIRMENT; METABOLIC SYNDROME X; METABOLISM; OBESITY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; X CHROMOSOME LINKED DISORDER;

ADIPOCYTES; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM SIGNALING; CELL DIFFERENTIATION; CELLS, CULTURED; FATTY ACID-BINDING PROTEINS; GENETIC DISEASES, X-LINKED; GIGANTISM; HEART DEFECTS, CONGENITAL; HUMANS; INTELLECTUAL DISABILITY; METABOLIC SYNDROME X; OBESITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84922690722     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.241     Document Type: Article

References (35)

1. Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000; 11: 175-180.
2. Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL et al. Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry 1989; 28: 8683-8690.
3. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 2002; 165: 259-269.
4. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009; 23: 3865-3873.
5. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.
6. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-3396.
7. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002; 22: 1686-1691.
8. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7: 699-705.
9. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489-503.
10. Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 2009; 105: 326-334.
11. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413.
12. Tonjes A, Kralisch S, Lossner U, Kovacs P, Bluher M, Stumvoll M et al. Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein. Int J Obes (Lond) 2012; 36: 766-773.
13. Wabitsch M, Brenner RE, Melzner I, Braun M, Moller P, Heinze E et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord 2001; 25: 8-15.
14. Klausner RD, Donaldson JG, Lippincott-Schwartz J, Brefeldin A. insights into the control of membrane traffic and organelle structure. J Cell Biol 1992; 116: 1071-1080.
15. Tartakoff A, Vassalli P, Detraz M. Comparative studies of intracellular transport of secretory proteins. J Cell Biol 1978; 79: 694-707.
16. Beeler TJ, Jona I, Martonosi A. The effect of ionomycin on calcium fluxes in sarcoplasmic reticulum vesicles and liposomes. J Biol Chem 1979; 254: 6229-6231.
17. Pressman BC, Fahim M. Pharmacology and toxicology of the monovalent carboxylic ionophores. Annu Rev Pharmacol Toxicol 1982; 22: 465-490.
18. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006; 103: 6970-6975.
19. Cao H, Sekiya M, Ertunc ME, Burak MF, Mayers JR, White A et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013; 17: 768-778.
20. Nickel W, Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009; 10: 148-155.
21. Ayers SD, Nedrow KL, Gillilan RE, Noy N. Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. Biochemistry 2007; 46: 6744-6752.
22. Gillilan RE, Ayers SD, Noy N. Structural basis for activation of fatty acid-binding protein 4. J Mol Biol 2007; 372: 1246-1260.
23. Xie L, Boyle D, Sanford D, Scherer PE, Pessin JE, Mora S. Intracellular trafficking and secretion of adiponectin is dependent on GGA-coated vesicles. J Biol Chem 2006; 281: 7253-7259.
24. Xie L, O'Reilly CP, Chapes SK, Mora S. Adiponectin and leptin are secreted through distinct trafficking pathways in adipocytes. Biochim Biophys Acta 2008; 1782: 99-108.
25. Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005; 16: 543-548.
26. Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008; 118: 2640-2650.
27. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004; 110: 1492-1498.
28. Lamounier-Zepter V, Ehrhart-Bornstein M, Karczewski P, Haase H, Bornstein SR, Morano I. Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity. FASEB J 2006; 20: 1653-1659.
29. Look C, Morano I, Ehrhart-Bornstein M, Bornstein SR, Lamounier-Zepter V. Adipocyte-derived factors suppress heart contraction. Int J Obes (Lond) 2011; 35: 84-90.
30. Engeli S, Utz W, Haufe S, Lamounier-Zepter V, Pofahl M, Traber J et al. Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women. Heart 2013; 99: 944-948.
31. Lehmann F, Haile S, Axen E, Medina C, Uppenberg J, Svensson S et al. Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett 2004; 14: 4445-4448.
32. Ringom R, Axen E, Uppenberg J, Lundback T, Rondahl L, Barf T. Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors. Bioorg Med Chem Lett 2004; 14: 4449-4452.
33. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447: 959-965.
34. Look C, Morano I, Ehrhart-Bornstein M, Bornstein SR, Lamounier-Zepter V. BMS309403 directly suppresses cardiac contractile function. Naunyn Schmiedebergs Arch Pharmacol 2011; 384: 255-263.
35. Kralisch S, Ebert T, Lossner U, Jessnitzer B, Stumvoll M, Fasshauer M. Adipocyte fatty acid-binding protein is released from adipocytes by a non-conventional mechanism. Int J Obes (Lond) 2014; doi:10.1038/ijo.2013.232.